SLC5A2 and type 2 diabetes mellitus: Overall, the risk of ketoacidosis was 2-times higher among those allocated SGLT-2 inhibitors compared to placebo (2.03, 1.41-2.93; 159 events), and there was no evidence RRs varied among different patient groups (all het test p>0.05).